KUVATRIS THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable, Trade
KUVATRIS THERAPEUTICS, INC. reported Increase (Decrease) in Accounts Payable, Trade of $1.32 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2026-01-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2026-01-14
- KUVATRIS THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2024-09-30 was $103.64K, a 89.49% decline year-over-year.
- KUVATRIS THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2024-06-30 was $885.64K, a 397.08% increase year-over-year.
- KUVATRIS THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2024-03-31 was $326.23K, a 160.91% increase year-over-year.
- KUVATRIS THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2023-12-31 was -$833.26K, a 619.19% decline year-over-year.
- KUVATRIS THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2023 was $456.23K, a 380.67% increase from fiscal 2022.
- KUVATRIS THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2022 was $94.91K, a 73.06% decline from fiscal 2021.
- KUVATRIS THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2021 was $352.28K.
| Period end | Increase (Decrease) in Accounts Payable, Trade 3 month | Increase (Decrease) in Accounts Payable, Trade 6 month | Increase (Decrease) in Accounts Payable, Trade 9 month | Increase (Decrease) in Accounts Payable, Trade 12 month |
|---|---|---|---|---|
| 2024-09-30 | $103.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-01-14 | $989.27K derived: sum of 2 quarters · filed 2026-01-14 | $1.32M 10-Q · filed 2026-01-14 | $482.24K derived: sum of 4 quarters · filed 2026-01-14 |
| 2024-06-30 | $885.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-09-20 | $1.21M 10-Q · filed 2024-09-20 | $378.61K derived: sum of 3 quarters · filed 2024-09-20 | $1.36M derived: sum of 4 quarters · filed 2026-01-14 |
| 2024-03-31 | $326.23K 10-Q · filed 2024-05-13 | -$507.03K derived: sum of 2 quarters · filed 2024-05-13 | $479.26K derived: sum of 3 quarters · filed 2026-01-14 | $657.42K derived: sum of 4 quarters · filed 2026-01-14 |
| 2023-12-31 | -$833.26K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $153.02K derived: sum of 2 quarters · filed 2026-01-14 | $331.19K derived: sum of 3 quarters · filed 2026-01-14 | $456.23K 10-K · filed 2024-03-11 |
| 2023-09-30 | $986.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-01-14 | $1.16M derived: sum of 2 quarters · filed 2026-01-14 | $1.29M 10-Q · filed 2026-01-14 | $1.45M derived: sum of 4 quarters · filed 2026-01-14 |
| 2023-06-30 | $178.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-09-20 | $303.20K 10-Q · filed 2024-09-20 | $463.69K derived: sum of 3 quarters · filed 2024-09-20 | $475.00K derived: sum of 4 quarters · filed 2024-09-20 |
| 2023-03-31 | $125.04K 10-Q · filed 2024-05-13 | $285.53K derived: sum of 2 quarters · filed 2024-05-13 | $296.84K derived: sum of 3 quarters · filed 2024-05-13 | -$914.50K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $160.49K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $171.80K derived: sum of 2 quarters · filed 2024-03-11 | -$1.04M derived: sum of 3 quarters · filed 2024-03-11 | $94.91K 10-K · filed 2024-03-11 |
| 2022-09-30 | $11.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-16 | -$1.20M derived: sum of 2 quarters · filed 2023-11-16 | -$65.58K 10-Q · filed 2023-11-16 | |
| 2022-06-30 | -$1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$76.89K 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $1.13M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $352.28K 10-K · filed 2023-03-30 |